Hans D. Menssen

5.2k total citations · 2 hit papers
64 papers, 3.5k citations indexed

About

Hans D. Menssen is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hans D. Menssen has authored 64 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 21 papers in Oncology and 21 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hans D. Menssen's work include Monoclonal and Polyclonal Antibodies Research (20 papers), Chronic Myeloid Leukemia Treatments (19 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Hans D. Menssen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), Chronic Myeloid Leukemia Treatments (19 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Hans D. Menssen collaborates with scholars based in Switzerland, Germany and United States. Hans D. Menssen's co-authors include Andreas Hochhaus, Timothy P. Hughes, Richard A. Larson, Giuseppe Saglio, François Guilhot, Jerald P. Radich, Dario Neri, Michele Baccarani, Hagop M. Kantarjian and Andreas Menrad and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Hans D. Menssen

62 papers receiving 3.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

2017 797 citations Andreas Hochhaus, Richard A. Larson et al. profile →
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016 563 citations Andreas Hochhaus, Giuseppe Saglio et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans D. Menssen Switzerland	26	2.0k	1.5k	1.0k	882	772	64	3.5k
Nikolas von Bubnoff Germany	31	2.0k 1.0×	1.3k 0.9×	1.1k 1.1×	683 0.8×	1.1k 1.5×	138	4.1k
Taghi Manshouri United States	43	3.1k 1.6×	3.2k 2.1×	1.3k 1.2×	1.2k 1.4×	3.0k 3.9×	143	6.2k
Michael J. Mauro United States	40	3.9k 2.0×	3.1k 2.1×	918 0.9×	2.1k 2.4×	825 1.1×	234	5.3k
Cox Eb United States	8	1.3k 0.7×	1.2k 0.8×	685 0.7×	668 0.8×	565 0.7×	10	2.7k
David R. Stover United States	23	960 0.5×	408 0.3×	1.1k 1.1×	306 0.3×	1.4k 1.8×	47	3.0k
Shu Tamura Japan	8	2.5k 1.3×	1.6k 1.1×	713 0.7×	1.1k 1.3×	1.0k 1.3×	11	3.7k
Yaping Shou United States	25	1.8k 0.9×	1.5k 1.0×	686 0.7×	826 0.9×	1.1k 1.4×	68	3.1k
Eric Bleickardt United States	19	3.3k 1.7×	2.4k 1.6×	967 0.9×	1.6k 1.9×	763 1.0×	40	4.0k
Markus Warmuth United States	27	1.2k 0.6×	885 0.6×	930 0.9×	411 0.5×	1.7k 2.2×	48	3.1k
Kathryn S. Kolibaba United States	22	1.0k 0.5×	2.0k 1.3×	1.4k 1.3×	281 0.3×	710 0.9×	93	3.5k

Countries citing papers authored by Hans D. Menssen

Since Specialization

Citations

This map shows the geographic impact of Hans D. Menssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans D. Menssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans D. Menssen more than expected).

Fields of papers citing papers by Hans D. Menssen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans D. Menssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans D. Menssen. The network helps show where Hans D. Menssen may publish in the future.

Co-authorship network of co-authors of Hans D. Menssen

This figure shows the co-authorship network connecting the top 25 collaborators of Hans D. Menssen. A scholar is included among the top collaborators of Hans D. Menssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans D. Menssen. Hans D. Menssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Séchaud, Romain, et al.. (2024). Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants. Cancer Chemotherapy and Pharmacology. 93(5). 439–453. 2 indexed citations

Séchaud, Romain, et al.. (2024). Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants. Cancer Chemotherapy and Pharmacology. 94(4). 535–547. 1 indexed citations

Hartmann, Karin, Jason Gotlib, Cem Akin, et al.. (2020). Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. Journal of Allergy and Clinical Immunology. 146(2). 356–366.e4. 38 indexed citations

Hochhaus, Andreas, Giuseppe Saglio, Timothy P. Hughes, et al.. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30(5). 1044–1054. 563 indexed citations breakdown →

Hochhaus, Andreas, María Teresa Gómez‐Casares, Jesper Stentoft, et al.. (2016). Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood. 128(22). 3066–3066. 4 indexed citations

Hochhaus, Andreas, Giuseppe Saglio, Timothy P. Hughes, et al.. (2015). Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood. 126(23). 2781–2781. 16 indexed citations

Hughes, Timothy P., Andreas Hochhaus, Hagop M. Kantarjian, et al.. (2014). Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 99(7). 1204–1211. 37 indexed citations

Aloj, Luigi, Michela Aurilio, Ferdinando Frigeri, et al.. (2014). Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 41(5). 867–877. 25 indexed citations

Saglio, Giuseppe, Timothy P. Hughes, Richard A. Larson, et al.. (2013). Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. Journal of Clinical Oncology. 31(15_suppl). 7054–7054. 4 indexed citations

10.

Erba, Paola Anna, Burkhard Hirsch, Emilio Bombardieri, et al.. (2013). Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient. Journal of Cancer Research and Clinical Oncology. 140(1). 35–43. 23 indexed citations

11.

Papadia, Francesco, Roberto Patuzzo, Andrea Maurichi, et al.. (2012). Isolated limb perfusion with the tumor‐targeting human monoclonal antibody–cytokine fusion protein L19‐TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. Journal of Surgical Oncology. 107(2). 173–179. 66 indexed citations

12.

Eigentler, Thomas, Benjamin Weide, Filippo de Braud, et al.. (2011). A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. Clinical Cancer Research. 17(24). 7732–7742. 125 indexed citations

13.

Czabanka, Marcus, Simon Bayerl, Melina Nieminen-Kelhä, et al.. (2011). Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. European Journal of Cancer. 47(8). 1276–1284. 12 indexed citations

14.

Erba, Paola Anna, Martina Sollini, Roberto Boni, et al.. (2010). Results of a phase I/II dose-finding and efficacy study of the tumor-targeting 131I-L19SIP human recombinant mini-antibody in patients (pts) with cancer. 51. 1153–1153. 1 indexed citations

15.

Menssen, Hans D., et al.. (2008). Wachstumsfaktoren in der Pathogenese maligner Erkrankungen. DMW - Deutsche Medizinische Wochenschrift. 113(22). 904–906.

16.

Schliemann, Christoph, Alessandro Palumbo, Kathrin Zuberbühler, et al.. (2008). Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 113(10). 2275–2283. 115 indexed citations

17.

Szelényi, Hubert, E.D. Kreuser, Ulrich Keilholz, et al.. (2001). Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. Annals of Oncology. 12(1). 105–108. 3 indexed citations

18.

Rodeck, Ulrich, et al.. (1994). Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes. International Journal of Cancer. 59(1). 78–82. 62 indexed citations

19.

Rodeck, Ulrich, Meenhard Herlyn, Hans D. Menssen, Richard W. Furlanetto, & Hilary Koprowski. (1987). Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. International Journal of Cancer. 40(5). 687–690. 122 indexed citations

20.

Menssen, Hans D., Meenhard Herlyn, Ulrich Rodeck, & Hilary Koprowski. (1987). Rapid dissociation of adherent human tumor cells by ultrasound. Journal of Immunological Methods. 104(1-2). 1–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact